Investor Presentation March 2022 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target," or other similar terms or expressions that concern X4's expectations, strategy, plans, or inten ...

Investor Presentation November 2021 Forward-Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target," or other similar terms or expressions that concern X4's expectations, strategy, plans, or in ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2021 Earnings Conference Call November 4, 2021 9:05 AM ET Company Participants Dan Ferry - LifeSci Advisors Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Art Taveras - Chief Scientific Officer Diego Cadavid - Chief Medical Officer Conference Call Participants Zegbeh Jallah - ROTH Capital Leland Gershell - Oppenheimer Marc Frahm - Cowen & Company Stephen Willey - Stifel Operator Greetings and welcome to X4 Pharmaceuticals Third Quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the trans ...

| --- | --- | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | Developing treatments | | | | | designed to have a clear and profound impact for patients with rare diseases, including WHIM syndrome and uncommon cancers | | | | | September 2021 Investor Deck | | | | | | | | | Forward-Looking Statements 2 This presentation contains forward-looking statements within the mea ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q2 2021 Earnings Conference Call August 3, 2021 8:30 AM ET Company Participants Carey Gallant - Investor Relations, LifeSci Advisors Paula Ragan - Chief Executive Officer Adam Mostafa - Chief Financial Officer Art Taveras - Chief Scientific Officer Conference Call Participants Trevor Allred - Oppenheimer RK - H.C. Wainwright Zegbeh Jallah - ROTH Capital Partners Mayank Mamtani - B. Riley Financial Ben Shim - Canaccord. Operator Greetings, and welcome to X4 Pharmaceutic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition ...

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2021 Earnings Conference Call May 6, 2021 8:30 AM ET Company Participants Daniel Ferry - LifeSci Advisors Paula Ragan - CEO Adam Mostafa - CFO Art Taveras - Chief Scientific Officer Diego Cadavid - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Marc Frahm - Cowen Swayampakula Ramakanth - H.C. Wainwright Sahil Kazmi - B. Riley FBR Arlinda Lee - Canaccord Genuity Operator Greetings and welcome to X4 Pharmaceuticals First Quarter Financial a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transitio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________ FORM 10-K _____________________________________________________________________________________ (Mark One) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38295 ________________________________________________________________________________________ ...